TrialThe oncologist2024

A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR).

Kamal Kant Sahu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.